YWYanqing Wu

Yanqing Wu

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Yanqing Wu has a total of 171 co-authors. Here are the top co-authors by number of shared publications:

  • Jian Xiao

    Department of Wound Healing, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, China

    20 shared publications
  • Shufang Cai

    The Institute of Life Sciences, Engineering Laboratory of Zhejiang Province for Pharmaceutical Development of Growth Factors, Wenzhou University, Wenzhou, Zhejiang 325035, China

    8 shared publications
  • Beini Wang

    School of Pharmaceutical Science, Wenzhou Medical University, Wenzhou, Zhejiang 325035, China

    6 shared publications
  • Ke Xu

    Engineering Laboratory of Zhejiang Province for Pharmaceutical Development of Growth Factors, Biomedical Collaborative Innovation Center of Wenzhou, The Institute of Life Sciences, Wenzhou University, Wenzhou, China

    6 shared publications
  • Jingyu Xu

    The Institute of Life Sciences, Engineering Laboratory of Zhejiang Province for Pharmaceutical Development of Growth Factors, Wenzhou University, Wenzhou, Zhejiang 325035, China

    5 shared publications
  • Jun Xiong

    School of Pharmaceutical Sciences, Wenzhou Wound Repair and Regeneration Key Laboratory, Cixi Biomedical Research Institute, Wenzhou Medical University, 325000, Wenzhou, Zhejiang, China

    5 shared publications

Latest Publications

  • Open Access

    Type 2 Diabetes Promotes the Microglial Pyroptosis by Activating NLRP3 Inflammasome to Impede Remyelination After Spinal Cord Injury

    by Jingyu Xu, Li Fang, Tao Wei, Shufang Cai, Ran Chen, Bingbin Wang, Saiqun Nie, Yueqi Wu, Fuyi Yan, Jiaqin Shao, et al.

    Diabetes hinders nerve recovery after spinal cord injury (SCI). The complex pathological factors of diabetes increase the difficulty of treating diabetes combined with SCI. Maintaining normal microglial function is essential for SCI recovery. However, it is unclear whether diabetes hinders nerve recovery after SCI by influencing normal microglial function. This study explored the role and regulatory mechanism of diabetes in microglial function during SCI recovery. We constructed a type 2 diabetes (T2D) combined with SCI mouse model and confirmed that T2D hinders nerve repair after SCI. T2D blocked phagocytizing function of microglia in SCI mice, which results in increased myelin debris accumulation and poor remyelination. A mechanistic study demonstrated that T2D triggers activation of NLRP3 inflammasome by activating the RAGE–ROS–TXNIP axis and then induces excessive microglial pyroptosis, which consequently leads to considerable loss of microglia after SCI. Verapamil (VRP; a TXNIP inhibitor) treatment confirmed that TXNIP is necessary for NLRP3 inflammasome activation. Conditional microglial Caspase-1 gene knockout (KO) mice also confirmed that excessive microglial pyroptosis is an important inducing event for more severe nerve damage in T2D combined with SCI mice. Moreover, this T2D effect on increased microglial pyroptosis was also effectively reversed by N -acetyl- l -cysteine (NAC; an antioxidant) and N -benzyl-4-chloro- N -cyclohexylbenzamide (FPS-ZM1; a RAGE inhibitor). In conclusion, this study revealed that T2D induces increased microglial pyroptosis by activating the RAGE–ROS–NLRP3 axis, and then blocks remyelination after SCI, which strongly suggests that microglial pyroptosis may be the key target for treating T2D combined with SCI.


  • Inhibition of CD36 ameliorates mouse spinal cord injury by accelerating microglial lipophagy

    by Bei-Ni Wang, An-Yu Du, Xiang-Hang Chen, Ting Huang, Abdullah Al Mamun, Ping Li, Si-Ting Du, Yan-Zheng Feng, Lin-Yuan Jiang, Jie Xu, et al.

    Spinal cord injury (SCI) is a serious trauma of the central nervous system (CNS). SCI induces a unique lipid-dense environment that results in the deposition of large amounts of lipid droplets (LDs). The presence of LDs has been shown to contribute to the progression of other diseases. Lipophagy, a selective type of autophagy, is involved in intracellular LDs degradation. Fatty acid translocase CD36, a multifunctional transmembrane protein that facilitates the uptake of long-chain fatty acids, is implicated in the progression of certain metabolic diseases, and negatively regulates autophagy. However, the precise mechanisms of LDs generation and degradation in SCI, as well as whether CD36 regulates SCI via lipophagy, remain unknown. In this study, we investigated the role of LDs accumulation in microglia for SCI, as well as the regulatory mechanism of CD36 in microglia lipophagy during LDs elimination in vivo and in vitro. SCI was induced in mice by applying moderate compression on spina cord at T9-T10 level. Locomotion recovery was evaluated at days 0, 1, 3, 7 and 14 following the injury. PA-stimulated BV2 cells was established as the in vitro lipid-loaded model. We observed a marked buildup of LDs in microglial cells at the site of injury post-SCI. More importantly, microglial cells with excessive LDs exhibited elevated activation and stimulated inflammatory response, which drastically triggered the pyroptosis of microglial cells. Furthermore, we found significantly increased CD36 expression, and the breakdown of lipophagy in microglia following SCI. Sulfo-N-succinimidyl oleate sodium (SSO), a CD36 inhibitor, has been shown to promote the lipophagy of microglial cells in SCI mice and PA-treated BV2 cells, which enhanced LDs degradation, ameliorated inflammatory levels and pyroptosis of microglial cells, and ultimately promoted SCI recovery. As expected, inhibition of lipophagy with Baf-A1 reversed the effects of SSO. We conclude that microglial lipophagy is essential for the removal of LDs during SCI recovery. Our research implies that CD36 could be a potential therapeutic target for the treatment and management of SCI.


  • Chitosan oligosaccharides ameliorates maternal diabetes-induced embryonic neural tube defects via inhibitting excessive pyroptosis of neuroepithelial cells

    by Mei Zhou, Bingbin Wang, Shufang Cai, Tao Wei, Yanren Zhang, Li Fang, Saiqun Nie, Beini Wang, Biru Xiao, Jian Xiao, et al.


  • Open Access

    Over-activation of TRPM2 ion channel accelerates blood-spinal cord barrier destruction in diabetes combined with spinal cord injury rat

    by Susu Zhang, Jiaxin Zhao, Man Wu, Yongxiu Zhou, Xuejuan Wu, Anyu Du, Yibing Tao, Shanshan Huang, Shufang Cai, Mei Zhou, et al.

    Spinal cord injury (SCI) is a devastating neurological disorder that often results in loss of motor and sensory function. Diabetes facilitates the blood-spinal cord barrier (BSCB) destruction and aggravates SCI recovery. However, the molecular mechanism underlying it is still unclear. Our study has focused on transient receptor potential melastatin 2 (TRPM2) channel and investigated its regulatory role on integrity and function of BSCB in diabetes combined with SCI rat. We have confirmed that diabetes is obviously not conductive to SCI recovery through accelerates BSCB destruction. Endothelial cells (ECs) are the important component of BSCB. It was observed that diabetes significantly worsens mitochondrial dysfunction and triggers excessive apoptosis of ECs in spinal cord from SCI rat. Moreover, diabetes impeded neovascularization in spinal cord from SCI rat with decreases of VEGF and ANG1. TRPM2 acts as a cellular sensor of ROS. Our mechanistic studies showed that diabetes significantly induces elevated ROS level to activate TRPM2 ion channel of ECs. Then, TRPM2 channel mediated the Ca2+ influx and subsequently activated p-CaMKII/eNOS pathway, and which in turn triggered the ROS production. Consequently, over-activation of TRPM2 ion channel results in excessive apoptosis and weaker angiogenesis during SCI recovery. Inhibition of TRPM2 with 2-Aminoethyl diphenylborinate (2-APB) or TRPM2 siRNA will ameliorate the apoptosis of ECs and promote angiogenesis, subsequently enhance BSCB integrity and improve the locomotor function recovery of diabetes combined with SCI rat. In conclusion, TRPM2 channel may be a key target for the treatment of diabetes combined with SCI rat.


  • Open Access

    Diabetes-mediated elevated ferroptosis of endothelial cells accelerates blood- spinal cord barrier disruption in spinal cord injury rat

    by Man Wu, Susu Zhang, Jiaxin Zhao, Xuejuan Wu, Yongxiu Zhou, Anyu Du, Beini Wang, Shufang Cai, Mei Zhou, Ling Xie, et al.

    Diabetes significantly aggravates spinal cord injury (SCI). The pathological mechanisms underlying it were still unclear, particularly the role of diabetes on blood spinal cord barrier (BSCB) after SCI. Endothelial cells (ECs) are the important component of BSCB. Here, we built the type 1 diabetes (T1D) combined with SCI rat model and tried to elucidate the role of diabetes on ECs after SCI. We confirmed that SCI impairs the permeability of BSCB and then blocks the recovery of locomotor function of rat, more importantly, diabetes significantly exacerbates it. Diabetes obviously induced the elevated ferroptosis level of ECs in spinal cord after SCI. Ferrostatin-1(Fer-1, ferroptosis inhibitor) administration significantly suppressed the ferroptosis level of ECs, and subsequently reversed the adverse role of diabetes on BSCB permeability and locomotor function of SCI rat. Mechanistic studies further observed that diabetes significantly activates RAGE signaling in ECs and induces excessive oxidative stress with abundance of ROS and abnormal mitochondria function in vivo and in vitro. After SCI, Fer-1 treatment also ameliorated diabetes-induced excessive oxidative stress level of ECs in spinal cord. Additionally, the human umbilical vein endothelial cells (HUVECs) were co-treated with high glucose, high lipid and H2O2 to mimic diabetes combined with SCI condition. The role of hyperglycemia on ferroptosis of ECs were also verified in vitro. In summary, diabetes significantly triggered the ferroptosis level of ECs via inducing elevated oxidative stress, and thus aggravated BSCB destruction of SCI rat, suggesting that ferroptosis will be a key target for the treatment of diabetes combined with SCI.

  • Pyroptosis in acute pancreatitis and its therapeutic regulation

    by Abdullah Al Mamun, Suzia Aktar Suchi, Abdul Aziz, Muhammad Zaeem, Fahad Munir, Yanqing Wu, Jian Xiao

    Pyroptosis defines a new type of GSDMs-mediated programmed cell death, distinguishes from the classical concepts of apoptosis and necrosis-mediated cell death and is prescribed by cell swelling and membrane denaturation, leading to the extensive secretion of cellular components and low-grade inflammatory response. However, NLRP3 inflammasome activation can trigger its downstream inflammatory cytokines, leading to the activation of pyroptosis-regulated cell death. Current studies reveal that activation of caspase-4/5/11-driven non-canonical inflammasome signaling pathways facilitates the pathogenesis and progression of acute pancreatitis (AP). In addition, a large number of studies have reported that NLRP3 inflammasome-dependent pyroptosis is a crucial player in driving the course of the pathogenesis of AP. Excessive uncontrolled GSDMD-mediated pyroptosis has been implicated in AP. Therefore, the pyroptosis-related molecule GSDMD may be an independent prognostic biomarker for AP. The present review paper summarizes the molecular mechanisms of pyroptotic signaling pathways and their pathophysiological impacts on the progress of AP. Moreover, we briefly present some experimental compounds targeting pyroptosis-regulated cell death for exploring novel therapeutic directions for the treatment and management of AP. Our review investigations strongly suggest that targeting pyroptosis could be an ideal therapeutic approach in AP.


  • Open Access

    Author Correction: Inhibition of Endoplasmic Reticulum Stress Preserves the Integrity of Blood-Spinal Cord Barrier in Diabetic Rats Subjected to Spinal Cord Injury

    by Zili He, Shuang Zou, Jiayu Yin, Zhengzheng Gao, Yanlong Liu, Yanqing Wu, Huacheng He, Yulong Zhou, Qingqing Wang, Jiawei Li, et al.

  • Open Access

    Minocycline improves the functional recovery after traumatic brain injury via inhibition of aquaporin-4

    by Qi Lu, Jun Xiong, Yuan Yuan, Zhanwei Ruan, Yu Zhang, Bo Chai, Lei Li, Shufang Cai, Jian Xiao, Yanqing Wu, et al.

    Traumatic brain injury (TBI) is one of the main concerns worldwide as there is still no comprehensive therapeutic intervention. Astrocytic water channel aquaporin-4 (AQP-4) system is closely related to the brain edema, water transport at blood-brain barrier (BBB) and astrocyte function in the central nervous system (CNS). Minocycline, a broad-spectrum semisynthetic tetracycline antibiotic, has shown anti-inflammation, anti-apoptotic, vascular protection and neuroprotective effects on TBI models. Here, we tried to further explore the underlying mechanism of minocycline treatment for TBI, especially the relationship of minocycline and AQP4 during TBI treatment. In present study, we observed that minocycline efficaciously reduces the elevation of AQP4 in TBI mice. Furthermore, minocycline significantly reduced neuronal apoptosis, ameliorated brain edema and BBB disruption after TBI. In addition, the expressions of tight junction protein and astrocyte morphology alteration were optimized by minocycline administration. Similar results were found after treating with TGN-020 (an inhibitor of AQP4) in TBI mice. Moreover, these effects were reversed by cyanamide (CYA) treatment, which notably upregulated AQP4 expression level in vivo. In primary cultured astrocytes, small-interfering RNA (siRNA) AQP4 treatment prevented glutamate-induced astrocyte swelling. To sum up, our study suggests that minocycline improves the functional recovery of TBI through reducing AQP4 level to optimize BBB integrity and astrocyte function, and highlights that the AQP4 may be an important therapeutic target during minocycline treating for TBI.


  • Open Access

    Advances in the Relationship Between Pyroptosis and Diabetic Neuropathy

    by Jingyu Xu, Shufang Cai, Jiaxin Zhao, Ke Xu, Hao Ji, Chengbiao Wu, Jian Xiao, Yanqing Wu

    Pyroptosis is a novel programmed cell death process that promotes the release of interleukin-1β (IL-1β) and interleukin-18 (IL-18) by activating inflammasomes and gasdermin D (GSDMD), leading to cell swelling and rupture. Pyroptosis is involved in the regulation of the occurrence and development of cardiovascular and cerebrovascular diseases, tumors, and nerve injury. Diabetes is a metabolic disorder characterized by long-term hyperglycemia, insulin resistance, and chronic inflammation. The people have paid more and more attention to the relationship between pyroptosis, diabetes, and its complications, especially its important regulatory significance in diabetic neurological diseases, such as diabetic encephalopathy (DE) and diabetic peripheral neuropathy (DPN). This article will give an in-depth overview of the relationship between pyroptosis, diabetes, and its related neuropathy, and discuss the regulatory pathway and significance of pyroptosis in diabetes-associated neuropathy.